Oncolytics Biotech Inc T.ONC

From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

[Noteable]

January 11, 2023 -  Ambrx Snags $2 Billion Takeover @$28/ per share - and- Harp acquired by Merck for $23/per share.

https://www.investors.com/news/technology/amam-stock-harp-stock-catapult-after-snagging-jnj-merck-buyouts/

[Noteable]

JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins Momentum in the Field of Rare Diseases  https://www.geneonline.com/jpm-2024-biotech-companies-mapping-out-their-future-and-a-new-round-of-ma-spree-begins/ In the United States and European Union, pancreatic cancer classifies as a rare disease, allowing drug developers to apply for orphan medicinal

[Noteable]

AMBRX BIOPHARMA, INC. Accumulated Deficit a/o September 30, 2023 was ($347,745,000) or ($4.87) per share

[Noteable]

AMBRX BIOPHARMA, INC. Accumulated Deficit a/o September 30, 2023 of USD ($4.87) per share is equivalent to ONCY's Accumulated Deficit of USD ($4.57) per share  a/o December 31, 2023.

[Noteable]

Ambrx is a Phase 1/2 clinical stage company 

[Noteable]

Ambryx was formed as a company 20 years ago.

[jh1970]

Ambryx market cap is 2B, for ONC it will be $25 US. Maybe this is a price if buyout will come.

[Noteable]

In contrast to Ambryx, ONCY has 2 Phase 3 ready registration studies - in mPDAC and mBC, which each have a particular value higher than Ambryx single Phase 1/2 clinical trial that brought the company $ 2 Billion.

[lonc17]

If Ambryx has Matt Coffey as thier CEO they would still be at $.52 And he would be happy collecitng his million dollar annual compensation. 

[13X2413]

How about a little it'sy bitsy run to $3.50.  Is that asking for too much?  At this point it is a.bit of fantasy, seeing what the share price does every week.  $3.50 is getting so far away. 

[jh1970]

100% agree, but $25us is a wishing price for buyout.

[atomicbombsta]

I'm looking at the Ambrx stock charts and don't see any evidence of a $3.50 price 3 month ago. Their 52 week low is $6.55 and their full chart only goes back to March 2023. Where did you get these $0.52 and $3.5 numbers from? Were they a different company before? 

[atomicbombsta]

My bad, found some better charts. Not sure what was up with all the ones I was looking at. The $0.52 is correct. Don't think the $3.50 is, but whatever, the general idea is there.

[Noteable]

"I'm looking at the Ambrx stock charts and don't see any evidence of a $3.50 price 3 month ago. .." .. well then try looking at the right chart which happens to be Harpoon (HARP).

[Buckhenry]

Who cares about ALL these other companies and what has happened to them. Unnoteable keeps bringing this up. It ain't oncy so it ain't worth talking about. We either don't have anything another company wants to buy or the management team sucks... I'm leaning toward the latter. 

[Azzak34]

Unbuckable, the point is that some were saying that given our share price, we wouldn't see a significant rise or buyout. These examples show that isn't true. It's also an indication of what companies with lesser drugs are fetching in the market.  It's sad that we keep having to spell this out for you. 

[inthno]

The situation is that one needs to do a comparable for a projection of a possible BO for the company. AMBRX is a different entity in  that they had done a phase 3 trial already in mbc and had favorable results that enrolled over 400 patients plus they had over 200 million in cash and investments. I am sure there are examples out there to compare but we all know that onc needs a bigger patient

[Azzak34]

Yuck. I'm beginning to question your motives now "De_man". For some one who calls himself "the man" and "in the know", you are glaringly not either of those things. 

[inthno]

let's stay away from personal attacks. I was only giving my opinion on timeframes and doing comparable and was not knocking the company. I guess we shall see what happens next and no one knows for sure what is going on, just a lot of hope and anticipation.

[Azzak34]

Nope, let's not. Your pathetic attempts to repeat the same nonsense everyday, while adding zero fact is sad. Your passive aggressive jabs are pathetic. I would encourage everyone to read this posters history and make your own judgment. 

[Buckhenry]

Folks just need to understand that assak et al... is in denial. They get quite upset and riot and burn when you upset their narrative. Their only avenue is to attack on a personal level. They are much like a wart on your tushy. It's there but is quite benign. 

[Buckhenry]

Folks just need to understand that assak et al... is in denial. They get quite upset and riot and burn when you upset their narrative. Their only avenue is to attack on a personal level. They are much like a wart on your tushy. It@s there but is quite benign.@

[Azzak34]

Oh unBuckable, I will miss your incoherence and terrible grammar when this is all over.  What actual stock are you invested in so we can stay in touch by railing against it on Stockhouse daily? 

[inthno]

Ok, Azzak, for you a most positive post. Looks like we will only be down about 10% for the week so looking up as far as I can see. Closed at 1.81 on Monday. Now for another reality, let's hope they start the folfirinox, panc trial this quarter and also the panc phase 3 mid year. That is what this company needs. NO more small trials and then not continuing on. So yes we are looking for either

[Azzak34]

Nobody wants a FUD spreading whinge. We're going to continue to get beat up until more news comes out.  For the umpteenth time. This company will be worth many multiples of where it's at once they announce partners and Phase 3's. Then it'll make millionaires thereafter, if you're willing to wait for it.  Until then sit and take the beating or get out. Suck it up and

[Quentin30]

Price will certainly rise on announcement of a partner, but I'm not so sure the rise will be significant for announcement of Phase III (if no partner is announced). I listened again to a presentation Matt made in 2017, where he states that they are now a Phase III company... that broadcast is getting on for 6 and a half years old... Where some are posting here that ONCY is Phase III ready

[Azzak34]

More nonsense Quenty.  It's hardly misleading that we're phase 3 ready. We have met the standards for moving to Phase 3 and have just added a board member who specializes in taking Biotechs to and through Phase 3. Look who's been added to our Board and Advisors recently. This company has never been here before with this board in place. You'll have to let the past go. 

[Quentin30]

No Azzak, not Phase III ready until the protocol is approved, and the sites ready to recruit... This has not happened yet... so Phase III remains aspirational... We've had 3 CMOs over the past 6 and a half years... and Coffey has been stating, we're Phase III ready all that time... hmm, you could argue that since we recieved a SPA from FDA to conduct a 450 patient study in mBC with a

[Azzak34]

Were we or were we not ready when Pancan was involved? We're certainly further back with Breast but Pancrearic will be there or very close.  Again. Use whatever logic is left in your brain and think why why Bizarri and Andrew's agreed to join us?! Read their Bio's then come back to me with thoughts on why them and why now!! 

[Noteable]

In ONCY's case being Phase 3-ready means that ONCY could receive an Accelerated Approval from the FDA in advance of any protocol and in advance of the enrollment of any patients into a confirmatory Phase 3 clinical study. https://www.lawinsider.com/dictionary/phase-iii-ready Since ONCY's pelareorep is a biologic that is able to treat several rare diseases,  its all a matter of

[inthno]

misleading for sure especially when Matt himself said that he expected to be running 2 phase 3 trials starting in 2023. Now it's anticipation for panc and only guidance for the phase 3. Not making any of this up,just the facts. And quentin is right , they could have started the trial 6 years ago and even stated such in their older pr's if you care to actually take a look. I'll make you

[Azzak34]

This is why you're boring. Again, we all know the history and the woulda, coulda, shoulda's. If those past mistakes mean you have no confidence then you just sell and go away.  Instead of emailing everyone in the board and getting nowhere spend a minute and watch the trading patterns. We are 100% being manipulated and will continue to be until the announcements.  I'll make

[Quentin30]

How did your last bet with me work out..??  from selling ONCY and buying into CRSP when I told you it would be the better trade through to year end, I've made 70% (yah I missed out on the high). In the meantime the price of ONC has cratered 25%. So, I'm now able to buy back the stake I sold, effectively for zero cost... but yah, just pennies right..!! But this stock still has more

[Azzak34]

Haha I'd be careful referring back to old bets with us. I do believe I saved you some of your pennies with your Crispy hodl. And by the way, it was actually close even though you were calling for it to moon.  Anyway, I'm glad you've abandoned your dopey argument. Really shows you have zero conviction on any of your calls. Crispy might pop a bit more but the explosion happens here

[Buckhenry]

I'm sure glad assak told us how things are going to go this year. I feel sooooo much better. They have only had to readjust their crystal ball for the 100th time in the last few years but I'm sure they are on target now. Just waiting to buy that oceanfront property in Arizona...

[Noteable]

In response to inthno - although AMBRX completed a Phase 3 in China - there is no transferability of results to either the United States or the European Union (EU). What inthno wants everyone to believe is that AMBRX was further along than it really is. One doesn't need to spend time in asking the question of why he seeks to misinform. The simple fact is that AMBRX is still a Phase 1/2